We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Bring photo ID to vote Check what photo ID you'll need to vote in person in the General Election on 4 July.
Report from the Advisory Council on the Misuse of Drugs (ACMD) on the classification and schedule of Remimazolam.
Recent information relating to COVID-19 vaccines and medicines that has been published since the November 2021 issue of Drug Safety Update, up to 3 December 2021.
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
The Medicines and Healthcare products Regulatory Agency has today issued a recall asking patients to return affected products.
Prulab Pharma Limited is recalling a batch of Cloipidogrel Oral Solution 75mg in 5ml due to a discrepancy with the product labelling that could result in an incorrect volume to be administered to the patient.
As the safety of COVID-19 antivirals in pregnancy has not been established, please report any pregnancies which occur during use of an antiviral, including paternal use, to the UK COVID-19 Antivirals Pregnancy Registry. This advice applies to molnupiravir (Lagevrio▼), the...
Broadcom’s deal to buy VMware could lead to less innovation and drive up the cost of computer parts used by government, banks and telecoms.
In view of data showing ongoing exposure to valproate in pregnancy, this article reminds healthcare professionals of the risks in pregnancy and the current Pregnancy Prevention Programme requirements, and provides information about the potential risks of valproate in other patients...
Increase the frequency of blood pressure monitoring to at least weekly for the first 2 months, and then monitor monthly for the first year and periodically thereafter during treatment, following recent reports of onset of severe hypertension (including rare cases...
Thousands of those most at-risk to COVID-19 will soon be able to access the UK’s second ground-breaking antiviral
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
The government responds to a report by the Advisory Council on the Misuse of Drugs (ACMD) regarding the classification and schedule of remimazolam (Byfavo).
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Employment Tribunal decision.
No one should stop taking valproate without advice from their healthcare professional
Groundbreaking new treatment to be rolled out to vulnerable hospital patients from next week.
The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out.
This new vaccine, VidPrevtyn Beta, has been authorised after meeting the MHRA’s required safety, quality and effectiveness standards.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).